Decentralized real-world study of digital therapeutic indicated for chronic insomnia enrolls first participant

Written by Ilana Landau, Editor
Medical devices, pharmaceuticals and vaccines Methodology Neurology and psychiatry News Real-world evidence

Pear Therapeutics (MA, USA) has announced that the first participant has been enrolled in its decentralized, real-world clinical study of an FDA-authorized prescription digital therapeutic indicated for adults with chronic insomnia. The 9-week long trial – termed the ‘DREAM’ study – plans to enroll approximately 350 adults with chronic insomnia to evaluate the effectiveness of Somryst™ as a treatment strategy for the condition. Somryst is a prescription-only digital therapeutic that provides a form of cognitive behavioral therapy for insomnia and can be used on smartphones and other mobile devices. The fully site-less, virtual clinical trial infrastructure of the DREAM study...

To view this content, please register now for access

It's completely free